Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Protein Name: | S100A8 |
Gene Name: | S100A8 |
Protein Full Name: | Protein S100-A8 |
Alias: | Calgranulin-A;Calprotectin L1L subunit;Cystic fibrosis antigen;Leukocyte L1 complex light chain;Migration inhibitory factor-related protein 8;S100 calcium-binding protein A8;Urinary stone protein band A |
Mass (Da): | 10835 |
Number AA: | 93 |
UniProt ID: | P05109 |
Locus ID: | 6279 |
COSMIC ID: | S100A8 |
Gene location on chromosome: | 1q21.3 |
Cancer protein type: | UNCLEAR |
Effect of cancer mutation on protein: | UNCLEAR |
Effect of active protein on cancer: | UNCLEAR |
Number of cancer specimens: | 19625 |
Percent of cancer specimens with mutations: | 0.17 |
Normal role description: | Calcium-binding protein - cytoplasmic and secreted. Has antimicrobial activity towards bacteria and fungi. Important for resistance to invasion by pathogenic bacteria. Up-regulates transcription of genes that are under the control of NF-kappa-B. Plays a role in the development of endotoxic shock in response to bacterial lipopolysaccharide (LPS). Promotes tubulin polymerization. Promotes phagocyte migration and infiltration of granulocytes at sites of wounding. Plays a role as pro-inflammatory mediator in acute and chronic inflammation and up-regulates the release of IL8 and cell-surface expression of ICAM1. Extracellular calprotectin binds to target cells and promotes apoptosis. Antimicrobial and proapoptotic activity is inhibited by zinc ions. Although S100A8 is upregulated in many cancer systems, it has been shown to be downregulated in esophageal cancer. Moreover, it is unclear whether this inflammatory protein is reacting to cancer development that has triggered the normal immune system, or whether these inflammatory pathways are hijacked by tumour cells to drive oncogenesis. |